Comment l EUCAST fixe les concentrations critiques (Breakpoints), Associations inhibiteurs de ß-lactamases et ß-lactamines. Nouvelles molécules
|
|
- Amos Phelps
- 5 years ago
- Views:
Transcription
1 Comment l EUCAST fixe les concentrations critiques (Breakpoints), Associations inhibiteurs de ß-lactamases et ß-lactamines Nouvelles molécules L. Dubreuil Maître de conférences en Pharmacologie Professeur de Bactériologie clinique
2 CEFTOLOZANE/TAZOBACTAM Structure Ceftolozane/tazobactam is a novel 3 -aminopyrazolium cephalosporin and β- lactamase inhibitor combination being developed as a 2:1 ratio for treatment of serious Gram-negative bacterial infections Ceftolozane/tazobactam = Zerbaxa 1.5 g q8h ou 3 g q8h Previous names: CXA-101, CXA-201, FR
3
4 Log 10 CFU/thigh at 24 h The Efficacy of Ceftolozane Correlates Best With %Time > MIC (%T>MIC) = Zerbaxa 4 Neutropenic mouse thigh infection model used to establish ceftolozane parameters 1 %T>MIC is the PK/PD measure most correlated with the in vivo efficacy of ceftolozane 10 9 R 2 = 20.0% R 2 = 45.9% R 2 = 61.0% C max /MIC h AUC/MIC Time>MIC R 2 represents the percentage of variance in colony forming unit (CFU)/thigh that can be attributed to each PK/PD index. AUC, area under the curve; MIC, minimum inhibitory concentration. Organism used: Klebsiella pneumoniae Craig and Andes. Antimicrob Agents Chemother. 2013;57: For Internal Training Purposes Only 4
5 In vitro PD model: Ceftolozane 5 Relationship between ft>mic and log reduction in 24 hr viable counts
6 Summary Pharmacodynamic Ceftolozane Targets 6 Stasis %T > MIC target of < 30% derived from neutropenic mouse thigh models for ceftolozane was lower than other cephalosporins %T>MIC does not change based on MIC Mean Stasis %T>MIC 1-log kill %T>MIC 2-log kill %T>MIC S. pneumoniae P. aeruginosa Enterobacteriaceae (wild-type) NA Enterobacteriaceae (ESBL producers) NA %T>MIC, percentage of time that the drug concentration exceeds minimum inhibitory concentration; ESBL, extended spectrum β-lactamase. 1. Lepak et al. Antimicrob Agents Chemother. 2014;58(10): Craig and Andes. Antimicrob Agents Chemother. 2013;57:
7 Change in Log 10 (CFU/mL) In Vitro Efficacy of Tazobactam Correlates Best With %Time > Threshold 7 Dose fractionation studies used to establish pharmacokinetic/pharmacodynamic (PK/PD) parameters of tazobactam in combination with ceftolozane The %Time > threshold concentration was the exposure measure most associated with tazobactam efficacy, regardless of enzyme expression CTX-M-15 producing Escherichia coli 2 0 R 2 = R 2 = R 2 = Dose fractionation schedule Control q24h q12h q8h q6h Construct of enzyme expression High β-lactamase Moderate β-lactamase Low β-lactamase AUC (mg/l h) C max (µg/ml) %Time > Threshold a a The threshold concentration was 0.05 mg/l for the low- and moderate-β-lactamase genetic constructs and 0.25 mg/l for the high-β-lactamase genetic constructs AUC, area under the plasma concentration-time curve; C max, maximum (peak) plasma drug concentration. VanScoy et al. Antimicrob Agents Chemother. 2013;57: For Internal Training Purposes Only 7
8 METHODS Monte Carlo Simulation 8
9 METHODS Monte Carlo Simulation 9
10 10 CEFTOLOZANE/TAZOBACTAM Monte Carlo Simulations Population PK parameters from the analysis were input into Pharsight Clinical Trial Simulator 1000 subjects were simulated Dosing regimen =1000 mg ceftolozane Q8h as a 1-hr infusion Intensive plasma sampling simulated on Day 7 Target attainment rates were determined for MICs ranging from mg/l Probability of target attainment by MIC MIC (mg/l) 30% T>MIC (%)
11 11 Probability of Target Attainment Against P. aeruginosa 1.0-g CEFTOLOZANE dose PTA is 94.7% for the 1 log 10 kill target against Pseudomonas with an MIC value up to 8 mg/l in plasma for the 1 g ceftolozane dose Melhem et al. ECCMID Poster P1743. T >CMI 40% For Internal Training Purposes Only 11
12 Probability of Target Attainment Against Enterobacteriaceae 1.5-g CEFTOLOZANE/TAZOBACTAM dose 12 PTA is 80.9% for the 1 log 10 kill target against Enterobacteriaceae with an MIC value up to 4 mg/l in plasma for the 1.5 g ceftolozane/tazobactam dose %T>MIC, percentage of time that the drug concentration exceeds minimum inhibitory concentration. Rubino et al. ICAAC Poster A
13 Probability of Target Attainment Against Enterobacteriaceae 1.5-g CEFTOLOZANE/TAZOBACTAM dose 13 PTA is 80.9% for the 1 log 10 kill target against Enterobacteriaceae with an MIC value up to 4 mg/l in plasma for the 1.5 g ceftolozane/tazobactam dose %T>MIC, percentage of time that the drug concentration exceeds minimum inhibitory concentration. Rubino et al. ICAAC Poster A
14 % of Isolates CEFTOLOZANE/TAZOBACTAM PACTS 2011: Comparative Activity Against Enterobacteriaceae Ceftolozane/tazobactam Ceftolozane Ceftazidime Piperacillin-Tazobactam MIC (mg/l) MIC (mg/l) Range MIC 50 MIC 90 % > 8 Ceftolozane/tazobactam Ceftolozane Ceftazidime Piperacillin/tazobactam PACTS: Program to Assess Ceftolozane/Tazobactam Susceptibility; JMI laboratories 2011 EU data: France (n=687), Germany (N=334), Italy (N=437), Spain (N=483), and UK (N=171)
15 15 Allure anormale de la courbe ceftolozane-tazobactam, Le problème n apparaît pas avec ceftazidime-avibactam
16 T >CMI 50% 2log Avibactam ft >1 mg/l 16
17 Simulated Target Attainment Data CAZ MIC (µg/ml) *C T =1 500mg CAZ/125mg NXL min infusion (Phase 2 cuti dose) 50% T>MIC & T>*C T 2000mg CAZ/500mg NXL min infusion (Phase 2 ciai dose) 50% T>MIC & T>*C T Zavicefta 2000mg CAZ/500mg NXL104 2-h infusion (Proposed Phase 3 dose) 50% T>MIC & T>*C T Thus a dose of 2000mg CAZ/500mg NXL104 given as a 2h infusion is intended for Phase 3
18 929 Shields novel ST258, clade II sublineage, which are not hypermutators
19 Tremendous new!
20 bicyclo-acyl hydrazide = BCH diazabicyclooctanes= DBO Nacubactam = Vaborbactam Relebactam VNRX 5133
21
22 Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection Johanna Berkhout, Maria J. Melcherset al. Antimicrobial Agents and Chemotherapy January 2016 Volume 60 1 We conclude that the effect of avibactam in combination with ceftazidime is dependent on the time above threshold %ft>ct 1mg/liter. The results found in this study are proposed to be applicable to designing and assessing human dosing regimens. %ft>ct 0,5 1 4
23
24 M. J. Melchers, E. et al. Ceftolozane-tazobactam AAC (12) The main PDI (pharmacokinetic/pd index (PDI)-response) that correlated with the effect of tazobactam was the ftct achieved with a CT of 0.5 mg/liter tazobactam.
25 The Relationship Between Tazobactam %T>Threshold and Change in Log 10 CFU PK/PD In Vitro Infection Model Ceftolozanetazobactam Seuil de tazobactam The threshold concentration identified for each isolate ranged from 0.5 to 4 mg/liter. Vanscoy B, Mendes RE, McCauley J, Bhavnani SM, Bulik CC, Okusanya OO, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG. Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane. Antimicrob Agents Chemother For Internal Training Purposes Only Dec;57(12):
26 CT = ½ CMI The enabling translational relationship for the tazobactam threshold that allowed comodeling of all four clinical isolates was the product of the individual isolate s ceftolozane-tazobactam MIC value (determined with a tazobactam concentration of 4 mg/liter) and 0.5. The tazobactam %Timethresholds associated with net bacterial stasis and 1- and 2- log10 CFU reductions in bacteria at 24h were 65.9, 77.3, and 90.2% of the dosing interval
27 Aztréonam-Avibactam
28 aztréonam
29 Johan W. Mouton Antimicrobial Agents and Chemotherapy 2017 Volume 61 Issue 9 Pharmacodynamics of Cefepime Combined with Tazobactam against Clinically Relevant Enterobacteriaceae in a Neutropenic Mouse Thigh Model Exposure-response relationships (ERRs) of tazobactam A sigmoidal maximum-effect (Emax) model was fitted to the data Time-dependent activity of tazobactam. The cumulative percentage that freedrug concentrations are above the threshold concentration over a period of 24 h [%ftct], The threshold concentration (CT) best correlating with tazobactam efficacy was 0.25 mg/ liter, as evidenced by the best fit of the percentage of time above the threshold concentration (%ftct) and response. A mean %ftct of 24.6% (range, 11.4 to 36.3%) for a CT of 0.25 mg/liter was required to obtain a bacteriostatic effect.
30 Dose fixe de cépépime on fait varier: les concentrations de Tazobactam les rythmes d administration du tazobactam Abaissement logarithmique de la charge bactérienne [Δlog10 CFU] dans la cuisse de souris The first approach was to determine the relationship between exposure and efficacy for a range of threshold levels and by visual inspection to decide which looked best.
31 To quantify these relationships, the R 2 for each of the plots was plotted against the concentration threshold value, and a fourth-order polynomial was fitted to the data points to allow calculation of the optimum value. ax 4 + bx 3 + cx 2 + dx + e = 0 Ferrari ( ) The calculated CT with the highest R 2 was subsequently used as the tazobactam threshold for each strain. 0,25mg/L
32 If CT is indeed the PK/PD index that best predicts efficacy, there should be a CT at which the %ftct response relationships of the q2h, q4h, and q6h regimens do not differ significantly from each other. Indépendance du régime d administration
33 Synthèse des concentrations seuils des inhibiteurs Agent Inhibiteur seuil d activité Antibiotique associé ft > CT T > CT T > CMI Ceftolozane-Tazobactam 0,5 (½ CMI) > 90% 35-50% Ceftazidime-Avibactam 1 50% 50% Aztréonam-Avibactam 2,5 50% 50% Céfépime-tazobactam 0,25 25% bactériostase Nacubactam-méropenem ¼ CMI L. Dubreuil 2018
34 MIC (mg/l) 30% T>MIC (%) La pharmaco vous dis je! Le Monte Carlo! Et la distribution des CMI? et la clinique?
35 cssti: clinical & microbiological success by MIC Gram-positive pathogens MIC (mg/l) S. aureus (all) n/n(%) MRSA n/n(%) MSSA n/n(%) β Streptococci n/n(%) /64 (100.0) /19 (94.7) /12 (100.0) 11/12 (91.7) /5 (100.0) /3 (100.0) - 3/3 (100.0) /79 (91.1) 73/79 (92.4) 148/156 (94.9) 149/156 (95.5) - 18/18 (100.0) 72/79 (91.1) 73/79 (92.4) 130/138 (94.2) 131/138 (94.9) /109 (93.6) 101/108 (93.5) 1/1 (100.0) /11 (100.0) 11/11 (100.0) /4 (50.0) 2/4 (50.0) - Total* 338/362 (93.4) 340/362 (93.9) 132/141 (93.6) 206/221 (93.2) 208/221 (94.1) /100 (99.0) 98/100 (98.0) Microbiological success n/n(%), Clinical or clinical and microbiological success n/n(%) (per isolate response, not per patient) *For isolates with susceptibility results available 35
36
37 The Novel β-lactamase Inhibitor, ETX-2514, (DBO)in Combination with Sulbactam Effectively Inhibits Acinetobacter baumannii
38 Activités comparées des inhibiteurs de ß-lactamases Agent KPC A MDL B ampc C Oxa D Pseudomonas aeruginosa MDR Acinetobacter baumannii MDR Avibactam-ceftazidime X N X v X N Aztreonam-Avibactam X X* X N N Relebactam-imipenem X X X Vaborbactam-Meropenem X N X N VNRX Céfépime X X X X X Zidebactam--Céfépime X X X X X X Nacubactam-Méropenem X X X v X X ETX Sulbactam X X X X * Entérobactérales L. Dubreuil 2018
39
40 Cefiderocol (S ), A Siderophore Cephalosporin,
41 Cumulative percentage (%) Antibacterial activity against CRE Carbapenem resistant Enterobacteriaceae (n=149) S CAMHB+apo-T Chelex-treated ISB CAMHB S Ceftazidime Meropenem MIC ( g/ml) The test strains include both KPC- and NDM-producers Ceftazidime, Meropenem: MIC was determined in CAMHB Influence du chélateur sur les valeurs de CMI de la sidérophore-céphalosporine S
42 Relationships between %T f>mic and Efficacy in Rat RTI Models Efficacy against MDR P. aeruginosa and A. baumannii Chelex treated ISB Test strains Results of rat infusion study MIC (µg/ml) %T f>mic 1-hour infusion P. aeruginosa ATCC hour infusion P. aeruginosa SR hour infusion (IMP-1 producer, MDRP) 3-hour infusion hour infusion A. baumannii hour infusion A. baumannii hour infusion (MDRA, CC92) 3-hour infusion hour infusion A. baumannii hour infusion A. baumannii hour infusion (MDRA) 3-hour infusion :Change from baseline control log 10 CFU/lung : -ca 2 log 10 reduction Conclusion: The probability of achieving a PK/PD exposure based on 75% of T f>mic in plasma is recommended to be the appropriate target to demonstrate the clinical efficacy of S
43
44
45 Triazaacénaphthylène Spiropyrimidénétrione No cross-resistance has been described
46 Polymyxin Spero Therapeutics is developing SPR 741, a lead potentiator candidate, a cationic peptide and a derivative of the compound polymyxin B, which interacts with.
47
48
49
Update on CLSI and EUCAST
Update on CLSI and EUCAST 1 Completed work» Cephalosporin breakpoints for Enterobacteriaceae ESBL screens MIC versus resistance mechanism» Carbapenem breakpoints for Enterobacteriaceae Modified Hodge Test»
More informationThe CLSI Approach to Setting Breakpoints
The CLSI Approach to Setting Breakpoints Jean B. Patel, PhD, D(ABMM) Deputy Director, Office of Antimicrobial Resistance Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic
More informationBasic Concepts of PK/PD -pharmacodynamic indices- Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodymamics
Basic Concepts of PK/PD -pharmacodynamic indices- Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodymamics This patient needs antibiotics. But which ones? Intensive care patient Ceftazidime,
More informationSCMID Online Lecture Library. by author. Optimizing antimicrobial therapy in the elderly. Dose Finding - The Past
Optimizing antimicrobial therapy in the elderly Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodynamics Dosing should be such that the level of antmicrobial activity is associated
More informationPharmacologyonline 1: (2010) ewsletter Singh and Kochbar. Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of
Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of Cefoperazone Sulbactam Singh M*, Kochhar P* Medical & Research Division, Pfizer India. Summary Antimicrobial resistance is associated with
More informationABSTRACT BRIEF REPORT. Alan J. Xiao. Luzelena Caro. Myra W. Popejoy. Jennifer A. Huntington. Ravina Kullar
Infect Dis Ther (2017) 6:137 148 DOI 10.1007/s40121-016-0143-9 BRIEF REPORT PK/PD Target Attainment With Ceftolozane/ Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function,
More informationDoripenem: pharmacokinetics and pharmacodynamics. Paul M. Tulkens, MD, PhD Françoise Van Bambeke, PharmD, PhD
16/04/2009 1 Doripenem: pharmacokinetics and pharmacodynamics Paul M. Tulkens, MD, PhD Françoise Van Bambeke, PharmD, PhD Unité de Pharmacologie cellulaire et moléculaire Louvain Drug Research Institute
More information%T MIC MIC. Pharmacokinetics PK: Cmax AUC T1/2 Pharmacodynamics PD: MIC: minimum inhibitory concentration time-killing-curve 1990.
THE JAPANESE JOURNAL OF ANTIBIOTICS 58 2 159( 55 ) ( 2 15 ) %T MIC MIC 2002 30%T MIC 50%T MIC 1000 mg 3 3 /day Pharmacokinetics PK: Cmax AUC T1/2 Pharmacodynamics PD: MIC: minimum inhibitory concentration
More informationReporting blood culture results to clinicians: MIC, resistance mechanisms, both?
Reporting blood culture results to clinicians: MIC, resistance mechanisms, both? Christian G. Giske, MD, PhD Senior Consultant Physician/Associate Professor Department of Clinical Microbiology Karolinska
More informationPharmacodynamics: the methods
Pharmacodynamics: the methods In vitro models Animal models Clinical studies Population studies With the support of Wallonie-Bruxelles-International 3B-1 Pharmacodynamics: the methods "un peu de tout "
More informationLong Half-life Drugs in Infectious Diseases: Implications and Complications
Long Half-life Drugs in Infectious Diseases: Implications and Complications In Session: Drugs That Just Won t Leave: From Stars of the Party to Unwelcome Guests Annual Meeting of the AAPS, San Diego, California
More informationExpert rules. for Gram-negatives
Academic Perspective in Expert rules Emerging Issues of Resistance in Gram-ve Bacteria for Gram-negatives Trevor Winstanley Sheffield Teaching Hospitals Presented on behalf of David Livermore University
More informationA Snapshot of Colistin Use in South-East Europe and Particularly in Greece
A Snapshot of Colistin Use in South-East Europe and Particularly in Greece Helen Giamarellou 02.05.2013 When Greek Physicians Prescribe Colistin? It is mainly prescribed in the ICU for VAP, bacteremia
More informationFocusing on beta-lactams and beta-lactamase inhibitors
New and Emerging Antibiotics: Data and Practical Recommendations Focusing on beta-lactams and beta-lactamase inhibitors Robert A. Bonomo, M.D. Medical Service, Louis Stokes Cleveland VAMC Department of
More informationDisclosures. Efficacy of the drug. Optimizing Dosing Based on PKPD- An overview. Dose Finding - The Past
Disclosures Optimizing Dosing Based on PKPD- An overview Johan W. Mouton MD PhD FIDSA FAAM Professor pharmacokinetics and pharmacodynamics Research grants advisory boards speaker This Patient Needs Antibiotics.
More informationConsultation on the Revision of Carbapenem Breakpoints
Consultation on the Revision of Carbapenem Breakpoints July 2018 Please send comments to the EUCAST Scientific Secretary at jturnidge@gmail.com by September 15. EUCAST revision of carbapenem breakpoints
More informationNew insights in antibiotic and antifungal therapy in the compromised host
New insights in antibiotic and antifungal therapy in the compromised host Claudio Viscoli University of Genova Ospedale Policlinico San Martino, Genova Potential conflicts of interest (last 5 years) Received
More informationNDA Briefing Document Anti-Infective Drugs Advisory Committee 05 December 2014
CEFTAZIDIME-AVIBACTAM FOR INJECTION for Treatment of Complicated Intra-abdominal Infection (used in combination with metronidazole), Complicated Urinary Tract Infection including Acute Pyelonephritis,
More informationActivity of Ceftolozane/Tazobactam Against a Broad Spectrum of Recent Clinical Anaerobic Isolates
AAC Accepts, published online ahead of print on 25 November 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.02253-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. Activity
More informationESCMID Online Lecture Library. by author
www.eucast.org EXPERT RULES IN ANTIMICROBIAL SUSCEPTIBILITY TESTING Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA Departamento de Microbiología II Universidad
More informationAntibiotic Usage Related to Microorganisms Pattern and MIC
Antibiotic Usage Related to Microorganisms Pattern and MIC DR. Dr. Latre Buntaran Sp.MK(K) Secretary General PERDALIN Head of Compartment of Infection Control PERSI Doripenem: Potent
More informationLa farmacologia in aiuto
Ferrara, 15 giugno 2018 La farmacologia in aiuto Pier Giorgio Cojutti, Federico Pea Istituto di Farmacologia Clinica Azienda Sanitaria Universitaria Integrata di Udine Therapeutic Drug Monitoring of Beta-Lactams
More informationFrequency of Occurrence and Antimicrobial Susceptibility of Bacteria from ICU Patients with Pneumonia
Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria from ICU Patients with Pneumonia Helio S. Sader, M.D.* Mariana Castanheira, Ph.D. Rodrigo E. Mendes, Ph.D. Robert K. Flamm, Ph.D. JMI
More informationJohan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodynamics
Exposure - Response Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodynamics ACTVITY in vitro (MIC) CONCENTRATIONS in vivo (PK) DOSING regimen Other factors ANTMICROBIAL EFFICACY (Microbiological
More informationCefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefotaxime Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationAntibiotic Treatment of GNR MDR Infections. Stan Deresinski
Antibiotic Treatment of GNR MDR Infections Stan Deresinski Kucers: The Use of Antibiotics 1st Edition 1972 392 pages Kucers: The Use of Antibiotics 7 th Edition 2017 5338 pages Carbapenem Susceptibility
More informationIn Vitro Activity of Ceftazidime-Avibactam Against Isolates. in a Phase 3 Open-label Clinical Trial for Complicated
AAC Accepted Manuscript Posted Online 21 November 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.01820-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10
More informationAchieving pharmacokinetic/pharmacodynamic (PK/PD) targets of β-lactams in critically ill patients at first dose: Can we do it with standard dosing?
Oral session: PK/PD-based optimized broad-spectrum beta-lactam therapy (Sunday 10 April, 11:30) Achieving pharmacokinetic/pharmacodynamic (PK/PD) targets of β-lactams in critically ill patients at first
More informationNightmare Bacteria. Disclosures. Technician Objectives. Pharmacist Objectives. Carbapenem Resistance in Carbapenem Resistance in 2017
Nightmare Bacteria How to Deal with the Reality of Carbapenem-resistant Organisms Disclosures I have no conflicts of interest relative to the content of this presentation Matthew L. Brown, Pharm.D., BCPS
More informationMechanisms of Resistance to Ceftazidime-Avibactam. Romney M. Humphries, PhD D(ABMM) Chief Scientific Officer Accelerate Diagnostics.
Mechanisms of Resistance to Ceftazidime-Avibactam Romney M. Humphries, PhD D(ABMM) Chief Scientific Officer Accelerate Diagnostics UCLA, January 2015 62 year old woman with advanced pancreatic cancer Vomiting
More informationNew treatments of multidrug-resistant Gram-negative ventilatorassociated
Review Article Page 1 of 22 New treatments of multidrug-resistant Gram-negative ventilatorassociated pneumonia Garyphallia Poulakou 1, Styliani Lagou 1, Drosos E. Karageorgopoulos 2, George Dimopoulos
More informationCeftolozane/tazobactam (Zerbaxa, Merck) September 2015 Inpatient Non-Formulary
Ceftolozane/tazobactam (Zerbaxa, Merck) September 2015 Inpatient n-formulary Criteria for Formulary Consideration of Ceftolozane/tazobactam Efficacy Ceftolozane/tazobactam was approved by the Food and
More informationComparison of Omadacycline and Tigecycline Pharmacodynamics in the Plasma, Epithelial Lining Fluid, and Alveolar Macrophages in Healthy Subjects
Comparison of Omadacycline and Tigecycline Pharmacodynamics in the Plasma, Epithelial Lining Fluid, and Alveolar Macrophages in Healthy Subjects Karolyn S. Horn, Mark H. Gotfried, Judith N. Steenbergen,
More informationGiving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help?
Giving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help? Pranita D. Tamma, M.D., M.H.S. Director, Pediatric Antimicrobial Stewardship Johns Hopkins University School of
More informationβ-lactamase inhibitors
β-lactamase inhibitors Properties, microbiology & enzymology DAVID M LIVERMORE Professor of Medical Microbiology, UEA Lead on Antibiotic Resistance, Public Health England β-lactamase classes A B C D Serine
More informationEvaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam
AAC Accepted Manuscript Posted Online 14 March 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.02969-15 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 2 Evaluation of the
More informationExpert rules in antimicrobial susceptibility testing: State of the art
Expert rules in antimicrobial susceptibility testing: State of the art ESCMID Postgraduate Education Course Antimicrobial Susceptibility Testing and Surveillance: from Laboratory to Clinic Hospital Universitario
More informationLessons from recent studies. João Gonçalves Pereira UCIP DALI
Lessons from recent studies João Gonçalves Pereira UCIP DALI 1 Patterns of Antimicrobial Activity Concentration C max Aminoglycosides Cmax/MIC>10 Metronidazol Area under the concentration curve Azithromycin
More informationThe Challenge of MDR and XDR infections Friday 14th September, Barcelona Multi-drug and Extremely drug-resistant Pseudomonas aeruginosa
The Challenge of MDR and XDR infections Friday 14th September, Barcelona Multi-drug and Extremely drug-resistant Pseudomonas aeruginosa Juan P. Horcajada Service of Infectious Diseases Hospital del Mar,
More informationOvercoming the PosESBLities of Enterobacteriaceae Resistance
Overcoming the PosESBLities of Enterobacteriaceae Resistance Review of current treatment options Jamie Reed, PharmD Pharmacy Grand Rounds August 28, 2018 Rochester, MN 2018 MFMER slide-1 Disclosure No
More informationAcademic Perspective in. David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic resistance PHE
Academic Perspective in Emerging No, we can t Issues treat of carbapenemase Resistance and ESBL in Gram-ve producers Bacteria based on MIC David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic
More informationContinuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook
Continuous Infusion of Antibiotics In The ICU: What Is Proven? Michael S. Niederman, M.D. Chairman, Department of Medicine Winthrop-University Hospital Mineola, NY Professor of Medicine Vice-Chairman,
More informationCefuroxime iv Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefuroxime iv Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the
More informationAntibacterial Antibiotic Resistancein 2016 What Should an Internist Know? Disclosures. Objectives 3/6/2016. Achaogen: Allergan:
Antibacterial Antibiotic Resistancein 2016 What Should an Internist Know? Michael Satlin, MD, MS Assistant Professor of Medicine Division of Infectious Diseases Weill Cornell Medicine March 4, 2016 1 Disclosures
More informationICU Volume 11 - Issue 3 - Autumn Series
ICU Volume 11 - Issue 3 - Autumn 2011 - Series Impact of Pharmacokinetics of Antibiotics in ICU Clinical Practice Introduction The efficacy of a drug is mainly dependent on its ability to achieve an effective
More informationAffinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED
AAC Accepts, published online ahead of print on February 00 Antimicrob. Agents Chemother. doi:./aac.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationTowards clinical Applications of PK-PD in specific situations
Towards clinical Applications of PK-PD in specific situations P.M. Tulkens Cellular and Molecular Pharmacology & Center for Clinical Pharmacy, Catholic University of Louvain, Brussels, Belgium with many
More informationMRSA Micro Scan Pos Combo 6J DADE BEHRING VCM
PKPD MRSA 1 1 2 1 1 2 17 1 26 17 3 16 vancomycinvcm methicillin-resistant Staphylococcus aureusmrsa 31 pharmacokineticpkparameter retrospective VCM 21 10 PK parameter Mann- Whitney U-test Cmax 37.1 µ gml29.942
More informationMONTE CARLO SIMULATION & PK-PD TARGET ATTAINMENT ANALYSIS:
MONTE CARLO SIMULATION & PK-PD TARGET ATTAINMENT ANALYSIS: Application to Estimation of MIC Breakpoints Paul G. Ambrose, Pharm.D. Director, Division of Infectious Diseases, Cognigen Corporation; Adjunct
More informationDiane M. Gomes, Pharm.D. Outcomes in Antimicrobial Stewardship Post-Doctoral Pharmacy Fellow Providence Veterans Affairs Medical Center
Diane M. Gomes, Pharm.D. Outcomes in Antimicrobial Stewardship Post-Doctoral Pharmacy Fellow Providence Veterans Affairs Medical Center The information disseminated in this lecture is given in my personal
More informationUse of imipenem. with the support of Wallonie-Bruxelles International. Magali Dodémont Microbiology Hospital Erasme Université Libre de Bruxelles
with the support of Wallonie-Bruxelles International Use of imipenem Magali Dodémont Microbiology Hospital Erasme Université Libre de Bruxelles 1 Β-lactams classification 2 Β-lactams: mode of action Inhibition
More informationEUCAST Frequently Asked Questions. by author. Rafael Cantón Hospital Universitario Ramón y Cajal, Madrid, Spain EUCAST Clinical Data Coordinator
EUCAST Frequently Asked Questions Rafael Cantón Hospital Universitario Ramón y Cajal, Madrid, Spain EUCAST Clinical Data Coordinator Erika Matuschek EUCAST Development Laboratory, Växjö Sweden Monday 24
More informationPharmacokinetic-Pharmacodynamic (PKPD) Modeling Characterizing Resistance for Predictions of Bacterial Kill in vivo
Pharmacokinetic-Pharmacodynamic (PKPD) Modeling Characterizing Resistance for Predictions of Bacterial Kill in vivo Anders Kristoffersson Pascale David- Pierson, Neil John Parrott, Olaf Kuhlmann, Thierry
More informationJournal of Infectious Diseases and
Journal of Infectious Diseases & Therapy ISSN: 2332-0877 Journal of Infectious Diseases and Therapy Santanirand et al., J Infect Dis Ther 2018, 6:5 DOI: 10.4172/2332-0877.1000378 Research Article Open
More informationEstimation of In Vitro Susceptibility Breakpoints for Tigecycline Against Staphylococcus aureus
Estimation of In Vitro Susceptibility Breakpoints for Tigecycline Against Staphylococcus aureus Alison K Meagher, PharmD Cognigen Corporation 45 th ICAAC December 17, 2005 Julie Passarell, M.A. Cognigen
More informationXERAVATM (eravacycline): A Novel Fluorocycline Antibacterial
XERAVATM (eravacycline): A Novel Fluorocycline Antibacterial Matteo Bassetti, MD, PhD Infectious Diseases Division University of Udine and Santa Maria Misericordia University Hospital Udine, Italy Disclosures
More informationESCMID Online Lecture Library. by author
Novel PK/PD data on the optimisation of colistin and the carbapenems Diamantis Plachouras Athens, Greece Hot Topics on Infections in the Critically Ill Patient, ESCMID Postgraduate Education Course, 31
More informationNew Antimicrobials: Now and In the Future
New Antimicrobials: Now and In the Future David C. Hooper, M.D. Division of Infectious Diseases Infection Control Unit Massachusetts General Hospital Harvard Medical School Conflicts of Interest Melinta
More informationProfessor of Chemotherapy Department of Preclinical and Clinical Pharmacology University of Florence
Professor of Chemotherapy Department of Preclinical and Clinical Pharmacology University of Florence Researching field Pharmacokinetics, Pharmacodynamics of antimicrobial, antifungal and antitumoral drugs
More informationPolymyxin B and Colistin Debate: One of the Same Kind or Mutt and Jeff?
Polymyxin B and Colistin Debate: One of the Same Kind or Mutt and Jeff? Bruce M. Jones, PharmD, BCPS Clinical Pharmacy Specialist Infectious Diseases St. Joseph's/Candler Health System, Inc. Clinical Adjunct
More informationESCMID Online Lecture Library. by author
Disclosures Pk/Pd of antifungal drugs Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodynamics Research grants advisory boards speaker Dosing should be such that the level of antmicrobial
More informationCHMP extension of indication variation assessment report
23 April 2015 EMA/CHMP/245949/2015 adopted Committee for Medicinal Products for Human Use (CHMP) Invented name: Tygacil International non-proprietary name: TIGECYCLINE Procedure No. EMEA/H/C/000644/II/0092
More informationTherapy of MDR/XDR Gram-negative bacteria: dealing with the devil. CRE: high dosing, how much? by author
Therapy of MDR/XDR Gram-negative bacteria: dealing with the devil CRE: high dosing, how much? George L. Daikos, MD National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece
More informationAdenium Biotech. Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes
Adenium Biotech Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes Board of Directors: - Stephan Christgau, PhD, chairman,
More informationVoriconazole Rationale for the EUCAST clinical breakpoints, version March 2010
Voriconazole Rationale for the EUCAST clinical breakpoints, version 2.0 20 March 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationDiscussion points CLSI M100 S19 Update. #1 format of tables has changed. #2 non susceptible category
Discussion points 2009 CLSI M100 S19 Update Nebraska Public Health Laboratory Changes most important to routine antimicrobial susceptibility testing. Documents available Janet Hindler discussion slide
More informationCarbapenem Disks on MacConkey agar as screening methods for the detection of. Carbapenem-Resistant Gram negative rods in stools.
JCM Accepts, published online ahead of print on 7 November 2012 J. Clin. Microbiol. doi:10.1128/jcm.02878-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Carbapenem Disks
More information2/6/14. What s Hot in ID Objectives
What s Hot in ID 2014 James S. Lewis II, Pharm.D., FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University Portland, OR Objectives Describe highlights of the Interscience Conference
More informationIn vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria
1 2 In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria 3 4 DAVID M LIVERMORE* 1,2, SHAZAD MUSHTAQ 1, MARINA WARNER 1,, ANNA VICKERS 1 AND NEIL WOODFORD 1 5 6 7 8 1 Antimicrobial
More informationIntegration of Target Site Pharmacokinetics and in-vitro Pharmacodynamics in the Assessment of Existing and New Anti-Infective Agents
Louvain Drug Research Institute Séminaire de pathologie infectieuse Integration of Target Site Pharmacokinetics and in-vitro Pharmacodynamics in the Assessment of Existing and New Anti-Infective Agents
More informationTP Larry Tsai, MD Chief Medical Officer Tetraphase Pharmaceuticals
TP-676 Larry Tsai, MD Chief Medical Officer Tetraphase Pharmaceuticals Tetraphase Pharmaceuticals Overview Tetraphase is developing novel antibiotics for serious and life-threatening Gram-negative MDR
More informationNational Center for Emerging and Zoonotic Infectious Diseases The Biggest Antibiotic Resistance Threats
National Center for Emerging and Zoonotic Infectious Diseases The Biggest Antibiotic Resistance Threats Jean B. Patel, PhD, D(ABMM) Science Lead, Antibiotic Resistance and Coordination Unit Centers for
More informationCarbapenem resistance has emerged worldwide in clinical isolates of Enterobacteriaceae. crossm
SUSCEPTIBILITY crossm In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae Meredith A. Hackel, a Olga Lomovskaya, b Michael N. Dudley, b James A. Karlowsky,
More informationWhat is new in EUCAST South Africa, May, Gunnar Kahlmeter EUCAST Technical Data Coordinator and Webmaster Sweden
What is new in EUCAST 2016 17 South Africa, May, 2016 Gunnar Kahlmeter EUCAST Technical Data Coordinator and Webmaster Sweden What is new in EUCAST 2016/17? New organisms with breakpoints (Addendum 2016)
More informationIn Vitro Susceptibility Pattern of Cephalosporin- Resistant Gram-Negative Bacteria
In Vitro Susceptibility Pattern of Cephalosporin- Resistant Gram-Negative Bacteria Warunee Punpanich MD*, Worraporn Tantichattanon MD**, Siriporn Wongwatcharapaiboon MD**, Vipa Treeratweeraphong BSc, MSc***
More informationAntibiotics to treat multi-drug-resistant bacterial infections
Antibiotics to treat multi-drug-resistant bacterial infections July 2013 JUNE 2013 Copyright 2013 Tetraphase Pharmaceuticals, Inc. 1 Forward Looking Statements and Other Important Cautions Any statements
More informationTherapeutic drug monitoring of β-lactams
CORATA Belgique Reims 1-2/10/2014 Therapeutic drug monitoring of β-lactams Frédéric Cotton Clinical Chemistry Erasme Hospital Faculty of Pharmacy ULB TDM of β-lactams β-lactams pharmacokinetics pharmacodynamics
More informationTreatment Strategies for Infections due to MDR-GNR
Treatment Strategies for Infections due to MDR-GNR Michael Satlin, MD Instructor in Medicine Division of Infectious Diseases Weill Cornell Medical College, New York, NY October 16, 2012 1 2 Faculty Disclosure
More informationPHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS
PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS SITI HIR HURAIZAH MD TAHIR Bpharm (UKM), MSc (Clinical Microbiology) (UoN) CLINICAL PHARMACIST HOSPITAL MELAKA WHY STUDY PHARMACOKINETICS (PK) AND PHARMACODYNAMICS
More informationPhenotypic detection of ESBLs and carbapenemases
Phenotypic detection of ESBLs and carbapenemases Standardized susceptibility testing residential workshop 2016 Katie Hopkins PhD Clinical Scientist Antimicrobial Resistance and Healthcare Associated Infections
More informationScreening and detection of carbapenemases
Screening and detection of carbapenemases For many isolates with carbapenemases the MICs of carbapenems are around the susceptible breakpoint making resistance difficult to detect - particularly with automated
More informationPharmacodynamic indices in targeting therapy of critical infections
Pharmacodynamic indices in targeting therapy of critical infections P.M. Tulkens Cellular and Molecular Pharmacology, Catholic University of Louvain, Brussels, Belgium & International Society of Anti-infective
More informationGurudatt Chandorkar, PhD 1,AlanXiao,PhD 1, Mohamad-Samer Mouksassi, PhD, FCP 2, Ellie Hershberger, PharmD 1, and Gopal Krishna, PhD 1.
Pharmacometrics Population Pharmacokinetics of Ceftolozane/ Tazobactam in Healthy Volunteers, Subjects With Varying Degrees of Renal Function and Patients With Bacterial Infections The Journal of Clinical
More informationIn vitro and in vivo Pharmacodynamics of Colistin and Aztreonam Alone and in Combination against Multidrug-Resistant Pseudomonas aeruginosa
Antimicrobial Section / Original Paper Received: April 12, 2016 Accepted: August 23, 2016 Published online: October 28, 2016 In vitro and in vivo Pharmacodynamics of Colistin and Aztreonam Alone and in
More informationNONFERMENTING GRAM NEGATIVE RODS. April Abbott Deaconess Health System Evansville, IN
NONFERMENTING GRAM NEGATIVE RODS April Abbott Deaconess Health System Evansville, IN OBJECTIVES Discuss basic limitations to assessing carbapenem resistance in nonfermenting GNRs Discuss antimicrobial
More informationReceived 30 March 2005; returned 16 June 2005; revised 8 September 2005; accepted 12 September 2005
Journal of Antimicrobial Chemotherapy (2005) 56, 1047 1052 doi:10.1093/jac/dki362 Advance Access publication 20 October 2005 Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity,
More informationMHSAL Guidelines for the Prevention and Control of Antimicrobial Resistant Organisms (AROs) - Response to Questions
MHSAL Guidelines for the Prevention and Control of Antimicrobial Resistant Organisms (AROs) - Response to Questions Dr. Andrew Walkty Medical Microbiologist, Diagnostic Services Manitoba (DSM) June. 17,
More informationOptimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria
Infect Dis Ther (2015) 4:391 415 DOI 10.1007/s40121-015-0093-7 REVIEW Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria Phillip J. Bergen Zackery P. Bulman Cornelia B. Landersdorfer
More informationR EVIEWS OF T HERAPEUTICS
R EVIEWS OF T HERAPEUTICS Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae Sarah Christina Jane Jorgensen, 1 and Michael Joseph Rybak 1,2,3, * 1 Anti-infective
More informationSurveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 41 41 Surveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia IRINA
More informationRevised AAC Version 2» New-Data Letter to the Editor ACCEPTED. Plasmid-Mediated Carbapenem-Hydrolyzing β-lactamase KPC-2 in
AAC Accepts, published online ahead of print on 3 December 2007 Antimicrob. Agents Chemother. doi:10.1128/aac.01180-07 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationRapid identification of emerging resistance in Gram negatives. Prof. Patrice Nordmann
Rapid identification of emerging resistance in Gram negatives Prof. Patrice Nordmann Emerging Resistance threats, CDC USA-2013 Enterobacteriaceae producing extendedspectrum β-lactamases (ESBL) Multi-resistant
More informationIs the package insert correct? PK considerations
Is the package insert correct? PK considerations Jason A Roberts B Pharm (Hons), PhD, FSHP Professor of Medicine and Pharmacy The University of Queensland, Australia Royal Brisbane and Women s Hospital,
More informationbreakpoints, cephalosporins, CLSI, Enterobacteriacae, EUCAST, review Clin Microbiol Infect 2008; 14 (Suppl. 1):
REVIEW Breakpoints for intravenously used cephalosporins in Enterobacteriaceae EUCAST and CLSI breakpoints G. Kahlmeter Department of Clinical Microbiology, Central Hospital, Växjö, Sweden ABSTRACT It
More informationControversial Issues in Susceptibility Testing: Point/Counterpoint. April N. Abbott, PhD D(ABMM) Romney M. Humphries, PhD D(ABMM)
Controversial Issues in Susceptibility Testing: Point/Counterpoint April N. Abbott, PhD D(ABMM) Romney M. Humphries, PhD D(ABMM) Disclosures RMH: Funding from BD, biomerieux, Beckman-Coulter, GenMark,
More informationMupirocin Rationale for the EUCAST clinical breakpoints, version th July 2010
Mupirocin Rationale for the EUCAST clinical breakpoints, version 1.0 6 th July 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationPlazomicin Versus Meropenem for the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: Results of the EPIC Study
Plazomicin Versus Meropenem for the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: Results of the EPIC Study Daniel J. Cloutier 1, Loren G. Miller 2, Allison S. Komirenko 1,
More informationPublic Health Surveillance for Multi Drug Resistant Organisms in Orange County
Public Health Surveillance for Multi Drug Resistant Organisms in Orange County Matt Zahn, MD Medical Director Epidemiology and Assessment Orange County Public Health Antimicrobial Mechanisms of Action
More informationActivity of tigecycline alone and in combination with colistin and meropenem against carbapenemase
Activity of tigecycline alone and in combination with colistin and meropenem against carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay Spyros Pournaras, Georgia Vrioni, Evangelia
More informationGuidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011
Guidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011 Objectives: To discuss the guidelines for detection of CRE in the laboratory setting. To review
More information